Details of Disease

General Information of Disease (ID: DISOIX6L)

• Disease Name: Cutaneous lupus erythematosus
• Synonyms: lupus erythematosus, cutaneous
• Disease Class: EB50-EB5Z: Cutaneous lupus erythematosus
• Definition: An autoimmune disorder that manifests as different lupus-specific skin disorders; it can occur with systemic lupus erythematosus, or as a singular disease.
• Disease Hierarchy:
  DISOKJWA: Lupus
  DISOIX6L: Cutaneous lupus erythematosus
• ICD Code:
  ICD-11: ICD-11: EB5Z
  ICD-10: ICD-10: L80-L99, L93
  ICD-9: ICD-9: 710
  Expand ICD-11: 'EB5Z
  Expand ICD-9: 710
• Disease Identifiers:
  MONDO ID: MONDO_0005282
  MESH ID: D008178
  UMLS CUI: C0024137
  MedGen ID: 7401
  SNOMED CT ID: 7119001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BIIB059	DMUDM2Y	Phase 3	NA	[1]
Litifilimab	DMBZN7J	Phase 3	Monoclonal antibody	[2]
Sirukumab	DMK8AQP	Phase 3	Monoclonal antibody	[3]
CC-11050	DM5AALL	Phase 2	NA	[4]
DNL758	DM89D6C	Phase 2	Small molecular drug	[5]
GLPG-0634	DMPHCDL	Phase 2	Small molecular drug	[1]
GS-5718	DMRKU0L	Phase 2	Small molecule	[6]
GS-9876	DM9Q2B6	Phase 2	NA	[1]
KRP-203	DMOW9X2	Phase 2	Small molecular drug	[7]
GSK2646264	DMQOM5V	Phase 1	NA	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
HLA-DQA1	TTU2I3J	moderate	Genetic Variation	[8]
IL3RA	TTENHJ0	Strong	Biomarker	[9]

This Disease Is Related to 12 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
TRIM21	OTA4UJCF	Limited	Biomarker	[10]
CSNK2B	OT2WW7R1	moderate	Genetic Variation	[8]
HLA-DQA2	OT1DH0N9	moderate	Genetic Variation	[8]
PSORS1C1	OT9HK436	moderate	Genetic Variation	[8]
RPP21	OT53MDNE	moderate	Genetic Variation	[8]
TRIM39	OTESLVP9	moderate	Genetic Variation	[8]
C1QA	OT6XKVVA	Strong	Genetic Variation	[11]
EIF2B5	OTV3R4RB	Strong	Biomarker	[12]
IFNK	OTO2WDPX	Strong	Biomarker	[13]
RO60	OTLGM5A8	Strong	Genetic Variation	[14]
RTRAF	OTJ6NVMW	Strong	Biomarker	[12]
TREX1	OTQG7K12	Strong	Genetic Variation	[15]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT05531565) A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST). U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT01856309) Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT01300208) To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT04781816) Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (CLEan). U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT04809623) A Randomized, Blinded, Placebo-Controlled, Phase 1b Study of GS-5718 in Subjects With Cutaneous Lupus Erythematosus (CLE). U.S.National Institutes of Health.
• [7] ClinicalTrials.gov (NCT01294774) Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus. U.S. National Institutes of Health.
• [8] Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus.Exp Dermatol. 2015 Jul;24(7):510-5. doi: 10.1111/exd.12708. Epub 2015 May 4.
• [9] Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T cell lymphoma.Histopathology. 2019 May;74(6):908-916. doi: 10.1111/his.13817. Epub 2019 Mar 20.
• [10] TWEAK/Fn14 Activation Participates in Ro52-Mediated Photosensitization in Cutaneous Lupus Erythematosus.Front Immunol. 2017 May 31;8:651. doi: 10.3389/fimmu.2017.00651. eCollection 2017.
• [11] Homozygous single nucleotide polymorphism of the complement C1QA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus.Lupus. 2003;12(2):124-32. doi: 10.1191/0961203303lu329oa.
• [12] Hypersensitive IFN Responses in Lupus Keratinocytes Reveal Key Mechanistic Determinants in Cutaneous Lupus.J Immunol. 2019 Apr 1;202(7):2121-2130. doi: 10.4049/jimmunol.1800650. Epub 2019 Feb 11.
• [13] Lupus Skin Is Primed for IL-6 Inflammatory Responses through a Keratinocyte-Mediated Autocrine TypeIInterferon Loop.J Invest Dermatol. 2017 Jan;137(1):115-122. doi: 10.1016/j.jid.2016.09.008. Epub 2016 Sep 16.
• [14] Human Ro60 (SSA2) genomic organization and sequence alterations, examined in cutaneous lupus erythematosus.Br J Dermatol. 2002 Feb;146(2):210-5. doi: 10.1046/j.1365-2133.2002.04618.x.
• [15] Familial chilblain lupus--a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1.Dermatology. 2009;219(2):162-6. doi: 10.1159/000222430. Epub 2009 May 28.